Niclas Eriksson, PhD
Niclas Eriksson, PhD
Biostatistician, Uppsala Clinical Research Center, UCR
Verified email at ucr.uu.se
Title
Cited by
Cited by
Year
Estimation of the warfarin dose with clinical and pharmacogenetic data
International Warfarin Pharmacogenetics Consortium
New England Journal of Medicine 360 (8), 753-764, 2009
16042009
Large-scale association analysis identifies new risk loci for coronary artery disease
P Deloukas, S Kanoni, C Willenborg, M Farrall, TL Assimes, ...
Nature genetics 45 (1), 25-33, 2013
14092013
A randomized trial of genotype-guided dosing of warfarin
M Pirmohamed, G Burnside, N Eriksson, AL Jorgensen, CH Toh, ...
N Engl J Med 369, 2294-2303, 2013
8202013
A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose
F Takeuchi, R McGinnis, S Bourgeois, C Barnes, N Eriksson, N Soranzo, ...
PLoS genetics 5 (3), e1000433, 2009
6942009
The largest prospective warfarin-treated cohort supports genetic forecasting
M Wadelius, LY Chen, JD Lindh, N Eriksson, MJR Ghori, S Bumpstead, ...
Blood, The Journal of the American Society of Hematology 113 (4), 784-792, 2009
6592009
Common VKORC1 and GGCX polymorphisms associated with warfarin dose
M Wadelius, LY Chen, K Downes, J Ghori, S Hunt, N Eriksson, ...
The pharmacogenomics journal 5 (4), 262-270, 2005
6042005
Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of …
N Wahlgren, N Ahmed, N Eriksson, F Aichner, E Bluhmki, A Dávalos, ...
Stroke 39 (12), 3316-3322, 2008
5362008
Association of warfarin dose with genes involved in its action and metabolism
M Wadelius, LY Chen, N Eriksson, S Bumpstead, J Ghori, C Wadelius, ...
Human genetics 121 (1), 23-34, 2007
4852007
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups
NA Limdi, M Wadelius, L Cavallari, N Eriksson, DC Crawford, MTM Lee, ...
Blood, The Journal of the American Society of Hematology 115 (18), 3827-3834, 2010
3602010
Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA
M Wieloch, A Själander, V Frykman, M Rosenqvist, N Eriksson, ...
European heart journal 32 (18), 2282-2289, 2011
3242011
Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA
M Wieloch, A Själander, V Frykman, M Rosenqvist, N Eriksson, ...
European heart journal 32 (18), 2282-2289, 2011
3242011
The genetics of blood pressure regulation and its target organs from association studies in 342,415 individuals
GB Ehret, T Ferreira, DI Chasman, AU Jackson, EM Schmidt, T Johnson, ...
Nature genetics 48 (10), 1171-1184, 2016
3052016
Genetic determinants of dabigatran plasma levels and their relation to bleeding
G Paré, N Eriksson, T Lehr, S Connolly, J Eikelboom, MD Ezekowitz, ...
Circulation 127 (13), 1404-1412, 2013
2402013
Integration of genetic, clinical, and INR data to refine warfarin dosing
P Lenzini, M Wadelius, S Kimmel, JL Anderson, AL Jorgensen, ...
Clinical Pharmacology & Therapeutics 87 (5), 572-578, 2010
2392010
Association of admission blood glucose and outcome in patients treated with intravenous thrombolysis: results from the Safe Implementation of Treatments in Stroke International …
N Ahmed, A Dávalos, N Eriksson, GA Ford, J Glahn, M Hennerici, ...
Archives of neurology 67 (9), 1123-1130, 2010
1702010
STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk
AK Abelson, AM Delgado-Vega, SV Kozyrev, E Sanchez, ...
Annals of the Rheumatic Diseases 68 (11), 1746-1753, 2009
1492009
STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk
AK Abelson, AM Delgado-Vega, SV Kozyrev, E Sanchez, ...
Annals of the Rheumatic Diseases 68 (11), 1746-1753, 2009
1492009
Prediction of warfarin dose: why, when and how?
N Eriksson, M Wadelius
Pharmacogenomics 13 (4), 429-440, 2012
1052012
Effect of genetic variations on ticagrelor plasma levels and clinical outcomes
C Varenhorst, N Eriksson, Å Johansson, BJ Barratt, E Hagström, ...
European heart journal 36 (29), 1901-1912, 2015
892015
Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy
BD Horne, PA Lenzini, M Wadelius, AL Jorgensen, SE Kimmel, PM Ridker, ...
Thrombosis and haemostasis 107 (02), 232-240, 2012
802012
The system can't perform the operation now. Try again later.
Articles 1–20